D3 Pharma and Encap Drug Delivery continue partnership
Livingston, United Kingdom, June 18th 2012
D3 Pharma Limited today announces its continuing partnership with Encap Drug Delivery to expedite the
commercial manufacturing and product licensing programme for its proprietary high-dose oral vitamin D3
product, PlenacholTM, for the treatment of vitamin D deficiency and insufficiency.
PlenacholTM is a patented liquid-filled capsule formulation of vitamin D3 which was developed in
conjunction with Encap and is available at three dose-strengths: 20,000, 40,000 and 100,000 international
units. PlenacholTM has a unique formulation base which is free from animal derived excipients and
peanut constituents. The utility of Encap’s world-class capsule liquid-filling technology secures
PlenacholTM as a first and best-in-class high-dose oral vitamin D3 product.
PlenacholTM will continue to be made available as a Specials product during the pre-license phase via
Encap Drug Delivery. For more information regarding PlenacholTM Specials supply please contact:
Dr Janice McLachlan (JMcLachlan@encapdrugdelivery.com).
About D3 Pharma
D3 Pharma is a privately owned specialty pharmaceutical company based in the United Kingdom. It is
committed to the research, development and commercialisation of licensed high-dose vitamin D3
medicinal products for the treatment of vitamin D deficiency, insufficiency and associated conditions. D3
Pharma’s pioneering work in the vitamin D deficiency area aims to address a significant unmet need and
improve vitamin D product access world-wide.
About Encap Drug Delivery
Encap Drug Delivery is the world’s largest contract development and manufacturing organization (CDMO)
totally dedicated to liquid and semi-solid (hot melt) filled capsules. The company was established in 1989
and is a global provider of oral drug delivery and pharmaceutical development services. The company
provides clients with fully integrated analytical and formulation development services, clinical trial
manufacturing and high volume commercial manufacturing. Encap’s state-of-the-art facility in the UK has
been audited by the FDA and MHRA and supplies clinical and commercial products to all major global
markets including EU, North and South America and Japan.
For further information please contact:
For further information please contact Dr Hiep Huatan, D3 Pharma Ltd (+44 1622 630057) or
Dr Stephen Brown, Encap Drug Delivery (+44 1506 448080).